US Recall News

United States Recall News Alerts for Recalled Drugs, Food, Products, & Vehicles

MENUMENU
  • Home
  • About
    • Advertise
  • Full Recall News Archive
    • Top Story

      J&J Settles Talc Mesothelioma Settlement

      By Sandra Dalton, Staff Writer On January 6, 2020, Superior Court Judge Stephen Kaus announced that Johnson & Johnsons (J&J) had agreed to … [Read More...]

      Salento Organics Issues Allergy Alert on Undeclared Milk in Dark Chocolate Fruit and Peanut Bites

      Summary Company Announcement Date: March 29, 2023 FDA Publish Date: … [Read More...]

    • More Safety Articles
    • Federal Preemption of State Product Liability Law
  • Drug Recalls
    • Abilify
    • Benicar
    • Fluoroquinolones
    • Invokana
    • Lipitor
    • Nuplazid
    • Opioids
    • OxyContin
    • Pradaxa
    • Proton Pump Inhibitors (PPIs)
    • Risperdal
    • SSRI
    • Symptoms & Side Effects
    • Taxotere
    • Testosterone
    • Uloric
    • Valsartan
    • Xarelto
    • Zofran
  • Medical Devices
    • 3M Earplug
    • 3T Heater-Cooler System
    • Bair Hugger
    • Bipolar Hip System
    • Essure
    • Hip Replacements
    • Implanon
    • IVC Filters
    • Hernia Mesh
    • Power Morcellators
    • Shoulder Implants
    • Transvaginal Mesh
  • Food Recalls
    • FDA Press Releases
    • USDA Press Releases
  • Auto Recalls
    • Air Bags
    • Ignitions
    • NHTSA Press Releases
    • Off-Road Utility Vehicles
    • Snowmobiles
    • Tires
  • Other Products
    • Asbestos
    • Baby Products
    • Pet Products
    • Roundup
    • Talcum Powder
    • Toy Recalls
You are here: Home / Food Recalls / FDA Press Releases / Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets

December 4, 2018 By The FDA Leave a Comment

Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochlorothiazide Tablets, USP (80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg strengths).

Out of an abundance of caution, these products are being recalled due to detected trace amounts of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Valsartan, USP, manufactured by Mylan Laboratories Limited. NDEA is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen according to the International Agency for Research on Cancer (IARC).

The finished products are manufactured by Mylan Pharmaceuticals Inc. and Mylan Laboratories Limited. These batches were distributed in the U.S. between March 2017 and November 2018.   The expanded recalled batches are as follows:

NDC Name and Strength Size Lot No Expiry
0378-1721-93 Amlodipine and Valsartan Tablets, USP  5/160 mg Bottles of 30 3064084 1/2019
0378-1721-93 Amlodipine and Valsartan Tablets, USP  5/160 mg Bottles of 30 3069629 5/2019
0378-1721-93 Amlodipine and Valsartan Tablets, USP  5/160 mg Bottles of 30 3073148 8/2019
0378-1721-93 Amlodipine and Valsartan Tablets, USP  5/160 mg Bottles of 30 3073149 8/2019
0378-1721-93 Amlodipine and Valsartan Tablets, USP  5/160 mg Bottles of 30 3076093 10/2019
0378-1721-93 Amlodipine and Valsartan Tablets, USP  5/160 mg Bottles of 30 3077772 11/2019
0378-1722-93 Amlodipine and Valsartan Tablets, USP 10/160 mg Bottles of 30 3064085 1/2019
0378-1722-93 Amlodipine and Valsartan Tablets, USP 10/160 mg Bottles of 30 3066063 3/2019
0378-1722-93 Amlodipine and Valsartan Tablets, USP 10/160 mg Bottles of 30 3069638 5/2019
0378-1722-93 Amlodipine and Valsartan Tablets, USP 10/160 mg Bottles of 30 3069639 6/2019
0378-1723-93 Amlodipine and Valsartan Tablets, USP 5/320 mg Bottles of 30 3064086 1/2019
0378-1723-93 Amlodipine and Valsartan Tablets, USP 5/320 mg Bottles of 30 3066061 3/2019
0378-1723-93 Amlodipine and Valsartan Tablets, USP 5/320 mg Bottles of 30 3066062 3/2019
0378-1723-93 Amlodipine and Valsartan Tablets, USP 5/320 mg Bottles of 30 3073145 9/2019
0378-1723-93 Amlodipine and Valsartan Tablets, USP 5/320 mg Bottles of 30 3073146 9/2019
0378-1723-93 Amlodipine and Valsartan Tablets, USP 5/320 mg Bottles of 30 3073147 9/2019
0378-1723-93 Amlodipine and Valsartan Tablets, USP 5/320 mg Bottles of 30 3076091 11/2019
0378-1723-93 Amlodipine and Valsartan Tablets, USP 5/320 mg Bottles of 30 3077619 11/2019
0378-1723-93 Amlodipine and Valsartan Tablets, USP 5/320 mg Bottles of 30 3082432 3/2020
0378-1724-93 Amlodipine and Valsartan Tablets, USP 10/320 mg Bottles of 30 3066064 3/2019
0378-1724-93 Amlodipine and Valsartan Tablets, USP 10/320 mg Bottles of 30 3069645 6/2019
0378-1724-93 Amlodipine and Valsartan Tablets, USP 10/320 mg Bottles of 30 3069646 6/2019
0378-1724-93 Amlodipine and Valsartan Tablets, USP 10/320 mg Bottles of 30 3073142 9/2019
0378-1724-93 Amlodipine and Valsartan Tablets, USP 10/320 mg Bottles of 30 3073143 9/2019
0378-1724-93 Amlodipine and Valsartan Tablets, USP 10/320 mg Bottles of 30 3073144 9/2019
0378-1724-93 Amlodipine and Valsartan Tablets, USP 10/320 mg Bottles of 30 3077617 11/2019
NDC Name and Strength Size Lot No Expiry
0378-5807-93 Valsartan Tablets, USP 40 mg Bottles of 30 3063780 1/2019
0378-5807-93 Valsartan Tablets, USP 40 mg Bottles of 30 3074879 10/2019
0378-5807-93 Valsartan Tablets, USP 40 mg Bottles of 30 3086684 6/2020
0378-5807-93 Valsartan Tablets, USP 40 mg Bottles of 30 3086687 6/2020
0378-5813-77 Valsartan Tablets, USP 80 mg Bottles of 90 3065445 2/2019
0378-5813-77 Valsartan Tablets, USP 80 mg Bottles of 90 3074880 10/2019
0378-5813-77 Valsartan Tablets, USP 80 mg Bottles of 90 3074883 10/2019
0378-5813-77 Valsartan Tablets, USP 80 mg Bottles of 90 3086688 6/2020
0378-5813-77 Valsartan Tablets, USP 80 mg Bottles of 90 3086689 6/2020
0378-5813-77 Valsartan Tablets, USP 80 mg Bottles of 90 3086710 6/2020
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3069019 5/2019
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3069020 5/2019
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3069021 5/2019
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3069022 5/2019
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3071354 7/2019
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3071355 7/2019
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3071357 7/2019
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3079023 1/2020
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3079027 1/2020
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3079028 1/2020
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3079029 1/2020
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3079996 2/2020
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3079997 2/2020
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3079998 2/2020
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3083635 4/2020
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3086715 6/2020
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3086716 7/2020
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3086717 7/2020
0378-5814-77 Valsartan Tablets, USP 160 mg Bottles of 90 3088623 8/2020
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3063783 1/2019
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3063784 1/2019
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3063785 1/2019
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3064092 1/2019
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3064093 1/2019
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3064094 1/2019
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3070349 6/2019
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3070350 6/2019
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3070351 6/2019
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3070352 6/2019
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3070353 6/2019
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3070354 6/2019
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3079030 1/2020
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3079031 1/2020
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3079032 1/2020
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3079033 1/2020
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3080011 2/2020
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3080224 2/2020
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3081498 3/2020
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3081500 3/2020
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3087126 7/2020
0378-5815-77 Valsartan Tablets, USP 320 mg Bottles of 90 3088476 8/2020
NDC Name and Strength Size Lot No Expiry
0378-6321-77 Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg Bottles of 90 3084363 2/2019
0378-6321-77 Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg Bottles of 90 3084364 2/2019
0378-6321-77 Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg Bottles of 90 3093800 12/2019
0378-6321-05 Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg Bottles of 500 3084363 2/2019
0378-6321-05 Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg Bottles of 500 3093800 12/2019
0378-6322-77 Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg Bottles of 90 2008880 8/2020
0378-6322-77 Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg Bottles of 90 3084358 2/2019
0378-6322-77 Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg Bottles of 90 3084359 2/2019
0378-6322-77 Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg Bottles of 90 3093801 12/2019
0378-6322-05 Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg Bottles of 500 3084359 2/2019
0378-6322-05 Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg Bottles of 500 3084361 2/2019
0378-6322-05 Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg Bottles of 500 3093801 12/2019
0378-6323-77 Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg Bottles of 90 3084887 2/2019
0378-6323-77 Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg Bottles of 90 3093802 12/2019
0378-6323-05 Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg Bottles of 500 3084887 2/2019
0378-6323-05 Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg Bottles of 500 3084888 2/2019
0378-6323-05 Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg Bottles of 500 3093802 12/2019
0378-6324-77 Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg Bottles of 90 3084889 2/2019
0378-6324-77 Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg Bottles of 90 3093803 12/2019
0378-6324-05 Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg Bottles of 500 3084890 2/2019
0378-6324-05 Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg Bottles of 500 3093803 12/2019
0378-6325-77 Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg Bottles of 90 3084860 2/2019
0378-6325-77 Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg Bottles of 90 3084861 2/2019
0378-6325-77 Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg Bottles of 90 3084862 2/2019
0378-6325-77 Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg Bottles of 90 3093804 12/2019
0378-6325-05 Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg Bottles of 500 3084862 2/2019
0378-6325-05 Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg Bottles of 500 3084863 2/2019

Valsartan is used for the treatment of high blood pressure for the treatment of heart failure, and to reduce cardiovascular mortality following myocardial infarction. Valsartan in combination with amlodipine or hydrochlorothiazide is used for the treatment of high blood pressure. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on valsartan should continue taking their medication, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment.

Mylan is notifying its distributors and customers by letter and is arranging for return of all recalled products. Wholesalers, retailers and consumers that are in possession of recalled product should contact Stericycle at 1-888-406-9305 for the return of the recalled product. Normal business hours are Monday through Friday 8 a.m. to 5 p.m. EST.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using these drug products.

  • Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: www.fda.gov/medwatch/report.htm
  • Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Share this:

  • Facebook
  • Twitter
  • LinkedIn
  • Email
  • Print

Related

Filed Under: FDA Press Releases, Valsartan

About The FDA

The Food and Drug Administration (FDA) is an agency within the U.S. Department of Health and Human Services. It consists of the Office of the Commissioner and four directorates overseeing the core functions of the agency: Medical Products and Tobacco, Foods and Veterinary Medicine, Global Regulatory Operations and Policy, and Operations.

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Facebook
Thomas Roney LLC
Economic Consulting

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Salento Organics Issues Allergy Alert on Undeclared Milk in Dark Chocolate Fruit and Peanut Bites

March 29, 2023 By The FDA

North American Food Distributing Company, Inc. Issues Allergy Alert on Undeclared Soy in 16.9 Fl Oz of Kagome Worcester Sauce and 16.9 Fl Oz of Kagome Chuno Sauce

March 27, 2023 By The FDA

Gilster-Mary Lee Corp. Issues a Recall for Undeclared Milk Allergen in HyVee Hamburger Chili Macaroni Skillet Meal

March 27, 2023 By The FDA

Hero Highlight

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Kawasaki Motors USA Recalls Engines Sold on Ferris and SCAG Riding Lawn Mowers Due to Burn and Fire Hazards

March 22, 2023 By The CPSC

Burnham Commercial Recalls Natural Gas Boilers Due to Burn Hazard (Recall Alert)

March 22, 2023 By The CPSC

Textron Specialized Vehicles Recalls Arctic Cat Alterra 600 and
Tracker 600 All-Terrain Vehicles (ATVs) Due to Crash Hazard
(Recall Alert)

March 22, 2023 By The CPSC

Ascend Laboratories LLC. Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules, USP 75 mg and 150 mg, Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity

March 21, 2023 By The FDA

Perfection Bakeries, d/b/a/ Aunt Millie’s Issues Allergy Alert on Undeclared Sesame in “Our Family Hot Dog Buns 8 Ct.”

March 21, 2023 By The FDA

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Ascend Laboratories LLC. Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules, USP 75 mg and 150 mg, Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity

March 21, 2023 By The FDA

Perfection Bakeries, d/b/a/ Aunt Millie’s Issues Allergy Alert on Undeclared Sesame in “Our Family Hot Dog Buns 8 Ct.”

March 21, 2023 By The FDA

Mutual Trading Co., Inc Issues Allergy Alert for Undeclared Soy in Sauces

March 20, 2023 By The FDA

Recall News in Your Inbox

Enter your email address to receive automated recall news updates.

Recent Comments

  • Roger McGowan on ABH NATURE’S PRODUCTS, INC, ABH PHARMA, INC., and STOCKNUTRA.COM, INC. Issues Nationwide Recall of All Lots of Dietary Supplement Products
  • Kathryn Moore on FDA Wants Cancer Warning on Breast Implants
  • BRAD on Huge ATV Recall by Polaris – Sportsman and Scrambler
  • Crystal Anderson on Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders
  • Outsourcing Training on The Modern Marketing of Pain
  • SANDRA Collett on Processed Food Preservative Linked to Autism?
  • Eric Karsh on Health Risks of Roundup Go Well Beyond Cancer

Recent Posts

  • Salento Organics Issues Allergy Alert on Undeclared Milk in Dark Chocolate Fruit and Peanut Bites
  • North American Food Distributing Company, Inc. Issues Allergy Alert on Undeclared Soy in 16.9 Fl Oz of Kagome Worcester Sauce and 16.9 Fl Oz of Kagome Chuno Sauce
  • Gilster-Mary Lee Corp. Issues a Recall for Undeclared Milk Allergen in HyVee Hamburger Chili Macaroni Skillet Meal
  • Jarman’s Midwest Cleaning Systems, Inc. Issues Voluntary Nationwide Recall of Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution and Isopropyl Alcohol Antiseptic 75% Topical Solution Hand Sanitizer Non-sterile Solution Due to Presence of Methanol
  • Second Nature Brands Issues Allergy Alert on Undeclared Wheat in Gluten Free Reese’s Pieces Brownie Brittle
  • Kawasaki Motors USA Recalls Engines Sold on Ferris and SCAG Riding Lawn Mowers Due to Burn and Fire Hazards
  • Burnham Commercial Recalls Natural Gas Boilers Due to Burn Hazard (Recall Alert)
  • Textron Specialized Vehicles Recalls Arctic Cat Alterra 600 and
    Tracker 600 All-Terrain Vehicles (ATVs) Due to Crash Hazard
    (Recall Alert)
  • Ascend Laboratories LLC. Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules, USP 75 mg and 150 mg, Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
-- See More Recall News

Disclaimer: The information contained in these topics is not intended nor implied to be a substitute for professional medical or legal advice, it is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider about any questions you may have regarding a medical condition. Nothing contained in these topics is intended to be used for medical diagnosis or treatment.


ATTORNEY ADVERTISING. The information provided on this website is not legal advice. No attorney-client relationship is formed by the use of this site. It is not stated or implied that a lawyer is certified as a specialist in any particular field of law. No results are guaranteed, and prior results do not guarantee a similar outcome. This site is informational, only, not dispositive; it is up to you to decide whether a particular lawyer is right for you. Use of this site is subject to your agreement to these.


Copyright © 2023 Altrumedia · Terms of Service · Log in